China's potential mRNA COVID vaccine weaker against Omicron-study

A Chinese mRNA vaccine candidate showed a sharper drop in neutralizing antibody activity against Omicron than against the non-mutated coronavirus in a small study, but a booster readily induced antibody production in animal tests, a research paper said. The ARCoV vaccine, jointly developed by the Academy of Military Medical Sciences (AMMS), Suzhou Abogen Biosciences and Walvax Biotechnology is currently being tested in an international Phase III clinical trial.